Head-to-head · WeighScore
FormidableMD vs Zealthy
The verdict
FormidableMD takes it — 73.2/100 to 46.7/100.
FormidableMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormidableMD is a physician-led, cash-pay telehealth practice based in Florida offering GLP-1 weight-loss treatment — semaglutide and tirzepatide in both FDA-approved and compounded forms, plus oral options…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FormidableMD | Zealthy |
|---|---|---|
| WeighScore | 73.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #71 | #496 |
| Semaglutide | $169/mo (1 mg dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $199/mo (10 mg dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 1 state | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #71 · C
Strengths
- Transparent, published dose-by-dose pricing for semaglutide ($169-$269/mo) and tirzepatide ($199-$319/mo) with no membership or commitment
- Offers both FDA-approved and compounded GLP-1s (plus oral options) from 503A pharmacies, with a real provider at every visit
- Boutique physician-led model bundling labs, peptides, HRT/TRT and urgent care; FSA/HSA eligible
Where it loses points
- Florida-focused telehealth — availability outside FL is not advertised, so out-of-state access is uncertain
- Medication cost is on top of a $199 initial consultation and $99 follow-up visits (pay-per-visit, not an all-in monthly price)
- The 503A compounding pharmacy partner is not named on the site
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.